Clinical trial · Interventional
A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme
A Single Arm Phase II Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme
NCT01115491CI-TRIAL-00016283completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Phase II, national, multicenter, open-label, non-comparative study to investigate the efficacy and safety of bevacizumab and temozolomide in patients with recurrent glioblastoma multiforme (GBM) after a first treatment failure. Patients will receive bevacizumab 10 mg/kg intravenously every two weeks until disease progression, consent withdrawal, or unacceptable toxicity. Anticipated time on study treatment is 12-24 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma Multiforme | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bevacizumab [Avastin] | Drug | Bevacizumab | ALIAS |
| temozolomide | Drug | Temozolomide | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- A
- interventionNames
- Drug: bevacizumab [Avastin]
- Drug: temozolomide
Primary outcomes (3)
- measure
- Progression-Free Survival (PFS) - Percentage of Participants With an Event
- timeFrame
- Baseline (BL), every 28 days, until progression, death or end-of-study, an average of 32 weeks
- description
- PFS was defined as the time, in weeks, from the date of inclusion in the study to the date of the first documentation of disease progression or death of the participant due to any cause. Participants that did not have an event at the time the analysis was performed were censored at the date of last contact. Participants that began a treatment other than those planned in this study (bevacizumab or temozolomide) were censored on the start date of the new treatment.
- measure
- PFS - Time to Event
- timeFrame
- BL, every 28 days, until progression, death or end-of-study, an average of 32 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>= 18 years * Histological diagnosis of glioblastoma multiforme (GBM) documented by surgical resection or biopsy. * They should be patients in a first relapse treated with radiotherapy and chemotherapy and chemotherapy based on temozolomide 150-200 mg/m2 on days 1 to 5 every 28 days (Stupp regimen) for at least three cycles. At least 4 weeks must have lapsed since previous chemotherapy and 3 months since the last dose of radiotherapy. * Use of an effective contraceptive method by patients and their partners. * Stable or decreasing corticosteroid dose for the five days prior to study entry * Adequate hematological function * Adequate liver function * Adequate kidney function Exclusion Criteria: * Signs of recent bleeding at the MRI of the brain. However, patients with clinically asymptomatic presence of hemosiderin, resolving bleeding changes related to surgery, and presence of punctate hemorrhage in the tumor will be allowed to participate in the study. * Prior treatment with bevacizumab * Poorly controlled arterial hypertension * History of hypertensive crises or hypertensive encephalopathy * New York Health Association (NYHA) Class II or higher congestive heart failure * History of myocardial infarction or unstable angina pectoris within six months of study entry * History of stroke or TIA within six months of study entry * Significant vascular disease within six months of study entry * History of hemoptysis \> grade 2 according to the NCI CTC criteria within one month of study entry * Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation) * Major surgery, open biopsy, intracranial biopsy, ventriculoperitoneal shunt, or major traumatic lesion within 28 days of study entry. * Core needle biopsy (excluding intracranial biopsy) or other minor surgery within seven days of randomization. Placement of a central vascular access device (CVAD) if performed in the two days prior to bevacizumab administration * History of abdominal fistula or gastrointestinal perforation within six months of study entry * History of intracranial abscess within six months of randomization * Any prior malignant neoplasm treated with curative intent in the five years prior to study entry, except for adequately controlled limited basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix * Patients with any other metabolic or psychological disease * Hypersensitivity to products derived from Chinese hamster ovary cells or to other humanized or recombinant human antibodies
References
Publications (0)
Data not yet available
No reference posted for this study.